Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Olomoucine (high purity)

CDK/cyclin inhibitor
ALX-350-013-M005 5 mg 100.00 USD
ALX-350-013-M025 25 mg 371.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: BML-CC200

Olomoucine is a purine derivative which acts as a potent and selective inhibitor of CDK1 (p34cdc2)/cyclin B and related kinases. It acts by competing for the ATP binding domain of the kinase. Of 35 protein kinases tested, olomoucine inhibited p33CDK2/cyclin A, p33CDK2/cyclin E, p34cdc2/cyclin B, p33CDK5/p35 and erk1 with IC50 of 7, 7, 7, 3 and 25µM respectively. The related kinases p34CDK4/cyclin D and p40CDK6/cyclin D3 were not inhibited or were less sensitive to olomoucine, IC50 > 1000 and 250µM respectively. PKC, PKA, PKG, CaM kinase II, MLC kinase, CK2, EGFR tyrosine kinase, p56lck, p56lyn, p60c-src, v-abl and insulin receptor tyrosine kinase are not inhibited or are weakly inhibited at 1mM. It delays mouse oocyte maturation and inhibits the growth of a variety of human cell lines including Rhabdomyosarcoma cell line Rh1, Rh18, Rh28 and Rh30; MCF-7, KB-3-1 and their adriamycin-resistant counterparts (IC50=18-86µM). It inhibits DNA synthesis in interleukin-2-stimulated T lymphocytes and triggers a G1 arrest similar to interleukin-2 deprivation. Can be used to synchronize cells in G1. Triggers apoptosis in target tumor cells in vitro and in vivo and in maturing cerebellar granule neurons. N9-Isopropyl-olomoucine and the negative control Iso-olomoucine are also available.

Product Details

Alternative Name:6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine
Appearance:White to off-white solid.
Solubility:Soluble in DMSO (32mg/ml), 100% ethanol (7mg/ml), or methanol.
Shipping:Ambient Temperature
Long Term Storage:-20°C
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons: E.A. Monaco, 3rd, et al.; Biochem. Pharmacol. 67, 1947 (2004), Abstract;
The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity: F. Alessi, et al.; Exp. Cell Res. 245, 8 (1998), Abstract;
Chemical inhibitors of cyclin-dependent kinases: L. Meijer, et al.; Meth. Enzymol. 283, 113 (1997), Abstract;
Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds: L. Havlicek, et al.; J. Med. Chem. 40, 408 (1997), Abstract;
Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases: R.T. Abraham, et al.; Biol. Cell 83, 105 (1995), Abstract;
Mitotic disassembly of the Golgi apparatus in vivo: T. Mistelli & G. Warren; J. Cell Sci. 108, 2715 (1995), Abstract;
R.T. Abraham, et al.; Biomed. J. 1, 32 (1994),
Inhibition of cyclin-dependent kinases by purine analogues: J. Vesely, et al.; Eur. J. Biochem. 224, 771 (1994), Abstract;